1,354 results on '"Herzog, Thomas J."'
Search Results
102. Prognostic significance of adenocarcinoma histology in women with cervical cancer
103. Contemporary management of endometrial cancer
104. State of the science: Contemporary front-line treatment of advanced ovarian cancer
105. ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients (pts) with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
106. HER2 in uterine carcinosarcoma: Testing platforms and implications for targeted therapy.
107. ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus investigator’s choice in advanced, platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian-tube cancer.
108. Practice changing cervical cancer clinical trials
109. Exploring the nuances between BRCA1 and 2: A multiomic analysis.
110. Pivotal study of ofra-vec (VB-111) combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).
111. Defining the limits of radical cytoreductive surgery for ovarian cancer
112. Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study
113. Endometrial cancer in the oldest old: Tumor characteristics, patterns of care, and outcome
114. A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q)
115. Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
116. Systematic mapping review of guidelines for BRCA1/2 genetic testing globally: investigating geographic and regional disparities in health equity for women and families at risk for hereditary ovarian cancer.
117. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: An exploratory analysis of a Gynecologic Oncology Group study
118. How does public policy impact cervical screening and vaccination strategies?
119. Long-term outcome and natural history of uterine adenosarcomas
120. SGO White Paper on Ovarian Cancer: Etiology, Screening and Surveillance
121. Sarcoma of the cervix: Natural history and outcomes
122. What is the role of HPV typing in the United States now and in the next five years in a vaccinated population?
123. Utility of cell salvage in women undergoing abdominal myomectomy
124. Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: Unraveling a mystery
125. A review of the current evidence for maintenance therapy in ovarian cancer
126. Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses
127. Latest research and treatment of advanced-stage epithelial ovarian cancer
128. Investigational agents in development for the treatment of ovarian cancer
129. Failure to rescue after major gynecologic surgery
130. Patterns of care for locally advanced vulvar cancer
131. Influence of Surgical Volume on Outcome for Laparoscopic Hysterectomy for Endometrial Cancer
132. The utility and cost effectiveness of preoperative computed tomography for patients with uterine malignancies
133. Risk and Predictors of Malignancy in Women with Endometrial Polyps
134. The utility of preoperative endometrial sampling for the detection of uterine sarcomas
135. Clinical Indications for Human Papillomavirus Vaccination
136. Feasibility and economic impact of same-day discharge for women who undergo laparoscopic hysterectomy
137. The commercialization of robotic surgery: unsubstantiated marketing of gynecologic surgery by hospitals
138. Microinvasive adenocarcinoma of the cervix
139. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer
140. Carboplatin dosing in obese women with ovarian cancer: A Gynecologic Oncology Group study
141. Age considerations when vaccinating against HPV
142. Initial lessons learned in HPV vaccination
143. Lymphadenectomy influences the utilization of adjuvant radiation treatment for endometrial cancer
144. Natural history and outcome of mucinous carcinoma of the ovary
145. The influence of surgical volume on morbidity and mortality of radical hysterectomy for cervical cancer
146. Morbidity and mortality of surgery for endometrial cancer in the oldest old
147. Predictors of massive blood loss in women with placenta accreta
148. Comparison of the prognostic significance of uterine factors and nodal status for endometrial cancer
149. An Economic Analysis of Robotically Assisted Hysterectomy
150. Comparative Effectiveness of Upfront Treatment Strategies in Elderly Women With Ovarian Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.